Prosarix
Curated by SignalComputational drug discovery company with proprietary platform for small molecule screening and design
Overview
Prosarix Ltd is a UK-based computational drug discovery company with a proprietary platform for drug screening and design. Their proprietary ProtoDiscovery™ platform/suite can be used for the identification and optimisation of small molecule ligands to specific targets. The suite contains three structure-based technologies namely ProtoScore™(Proprietary Scoring function), ProtoScreen™(for virtual screening), ProtoBuild™ (Small molecule de novo design tool) and two ligand-based technologies. ProtoShapeES™ (Electrostatic and molecule shape-based screening), ProtoClassify™ (Ligand classification using pharmacophore features). The company also has ProtoDiscovery™ Compound Database (PCD), which has a library of >5M compounds for screening. The company also offers EnzaCore™ SAR Explorer Panels, a set of products that can be used for the incorporation of chiral building blocks. Prosarix has an in-house discovery program focused on GPCR targets to identify and develop novel lead series for CNS. Prosarix claims that its advanced lead candidates from its in-house program have shown pre-clinical efficacy in models of pain, anxiety and depression. Prosarix was formed in 2007 following the acquisition of the platform from Amura Holdings.
Key facts
- Founded
- 2006
- Headquarters
- Cambridge, United Kingdom
- Stage
- Sign up to view
- Industry
- Health Technology
Business model
- 6 products and services
- Sign up to view
- Commercial model
- Sign up to view
Contact
- Sign up to view